logo oncology-news

Онкология  >  Новости онкологии

При финансовой поддержке logo MSD Oncology

Melanoma: questionable benefit for pembrolizumab with dabrafenib/trametinib

Grade 3-5 adverse events more than doubled with triplet therapy.